I-Jakafi ijolise kuMechanism Mechanism e-Polycythemia Vera

I-Jakafi imela iparadim yeentuthuko kwi-pharmacology.

Siphila kumaxesha amangalisa apho singayiqondi kakuhle ngakumbi iindlela zesifo kodwa nendlela yokujolisa ezi ndlela ngezilwanyana ezisanda kufunyanwa. Ngokomzekelo, i-Jakafi (i-ruxolitinib) yaba yiyayisisigqibo sokuqala se-FDA sokuphatha i- polycythemia vera , kwaye isebenza ngokuvimbela ama-enzymes uJanus Associated Kinase 1 (JAK-1) kunye noJanus Associated Kinase 2 (JAK-2).

Kanye nezinye iinguqu zamaselula, ezi enzyme ziya ku-haywire kubantu abane polycythemia vera.

Yintoni iPolycythemia Vera?

I-Polycythemia vera yintlungu engavamile yegazi. Isifo esibangelisayo esivame ukunikela emva koko ebomini (abantu kwiminyaka yabo engama-60) kwaye ekugqibeleni kubangela i-thrombosis (cinga ukuphazamiseka) kwisinye kwisithathu kubo bonke abantu abachaphazelekayo. Njengoko sonke sisazi, ukuphazamiseka kungabulala ngoko ukuxilongwa kwe-PV kunzima kakhulu.

Ibali lendlela u-PV uqala ngayo kwintolongo yethambo. Umongo wethu wethambo uxanduva lokwenza iiseli zethu zegazi. Iindidi ezahlukeneyo zeeseli zegazi emzimbeni wethu zineendima ezahlukileyo. Iiseli zegazi ezibomvu zihambisa i-oksijini kwiisisu kunye namalungu ethu, amangqamuzana egazi ezimhlophe anceda ukulwa nokusuleleka kunye neeplatelets ukuyeka ukuphuma. Kubantu abanePV, ​​kukho utshintsho kwiiseli ezininzi ze-hematopoietic ezenza umkhiqizo ogqithiseleyo weeseli ezibomvu zegazi, iiseli zegazi ezimhlophe kunye neeplatelet. Ngamanye amagama, kwi-PV, iiseli zangaphambili, ezahlula kwiiseli ezibomvu zegazi, iiseli zegazi ezimhlophe kunye neeplatelets, ziphonswa kwi-overdrive.

Uninzi lwento nayiphi na into engekho nto, kwaye kwimeko yePV, ezininzi iiseli zegazi zinokuthi zidibanise imilambo yethu yegazi ebangela zonke iintlobo zeengxaki zeklinikhi kubandakanywa oku kulandelayo:

I-PV inokukhuphaza nezinye izifo ezifana nesifo senhliziyo nesifo sengqondo segazi ngokubakho kwinani elongeziweyo leeseli zegazi ezijikeleza ukujikeleza kunye ne-muscular smooth hyperplasia okanye ukugqithisa okuqhubekayo kwandisa ukuhamba kwegazi. (Imisipha yomzimba yenza iindonga zemithambo yethu yegazi, kwaye inani elinyukayo yeeseli zegazi mhlawumbi likhupha izinto ezininzi zokukhula ezibangela ukuba i-muscle evulekileyo ikhule.)

Incinci yabantu abanePV iyaqhubeka nokuphuhlisa i-myelofibrosis (apho umongo wethambo usichithwa okanye "uphelelwe" kwaye uzaliswe nge-fibroblasts engenamsebenzi kunye ne-filler-like aemia) kwaye ekugqibeleni i-leukemia. Gcina ukhumbula ukuba i-PV idla ngokubizwa ngokuba yi- myeloproliferative neoplasm okanye umdlavuza ngoba njengamanye amagciwane angabangela ukunyuka kwamathambo kwiinombolo zeeseli. Ngelishwa, kwabanye abantu abanePV, ​​i-leukemia imele ukuphela komgca ngokuqhubeka komhlaza.

Jakafi: Imithi edibanisa i-Polycythemia Vera

Abantu kwisigaba se-plethoric se-PV okanye isigaba esibonakaliswe yinani elongeziweyo lamaseli egazi liphathwa ngamanyathelo angenelelo okunciphisa iimpawu kunye nokuphucula umgangatho wobomi. Ininzi eyaziwayo phakathi kwezi zonyango mhlawumbi i- phlebotomy okanye igazi lokunciphisa ukubalwa kweeseli zegazi.

Iingcali ziphinda ziphathe i-PV kunye ne-myelosuppressive (cinga i-chemotherapeutic) i-agents-hydroxyurea, i-busulfan, i-32p kwaye, ngoku kutshanje, i-interferon-leyo inqanda ukuveliswa okweqile kweeseli zegazi. Ukwelashwa kwe-Myelosuppressive kwandisa ingqondo yesigulane kwaye kucinga ukuba kunceda abantu abanePV baphile ixesha elide.

Ngelishwa, ezinye zeziyobisi ezifana ne-chlorambucil zithatha umngcipheko wokubangela i-leukemia.

Kwabantu abanePV abanenkathazo yokunyamezela okanye abangayiphenduliyo kwi-hydroxyurea, ummeli wokuqala we-myelosuppressive, uJakafi uvunyiwe yi-FDA ngoDisemba 2014. I-Jakafi isebenza ngokuvimbela i-JAK-1 ne-JAK-2 enzyme eguqulwa ngabantu abaninzi nePV. Ezi enzyme zibandakanyeka kwigazi kunye nokusebenza kwe-immunological, iinkqubo ezingavamile kubantu abanePV.

Kwimizuzu engama-21 yabantu abangenakuxhaswa okanye abangayithobeli i-hydroxyurea, uphando lubonisa ukuba i-Jakafi iyanciphisa ubukhulu be-spleen (iyanciphisa i-splenomegaly) kwaye iyanciphisa imfuno ye-phlebotomy. Uphando lubonisa ukuba nangona unyango olungcono lunokufumaneka, i-1 pesenti yabantu abanjalo babeya kufumana inzuzo enjalo. Ingqalelo, uJakafi wayevunywe ngaphambili ngu-FDA kunyango lwe-myelofibrosis ngo-2011. Iimpembelelo eziqhelekileyo eziqhelekileyo zikaJakafi (apho i-FDA ihambelana "nemiphumo emibi") ibandakanya i-anemia, ukubalwa kweeplatelet zegazi, ukuxakeka, ukutywina, kunye nokukhwabanisa.

Kufuneka kuqatshelwe ukuba njengokuba kunjalo nangonyango oluthile lwe-myelosuppressive, akucaci nokuba uJakafi uza kunceda abantu baphile ixesha elide.

Ukuba wena okanye umntu omthandayo unempembelelo engaphenduliyo kwi-hydroxyurea, i-Jakafi imela unyango olutsha oluthembisayo. Konke thina, i-Jakafi imela iparadiym yokubaluleka kokusetyenziswa kwamachiza okuya phambili. Abaphandi bahamba bhetele ekuqaliseni ukuba zeziphi iindlela eziphazamiseka zizifo kwaye zijolise kule ngozi.

Imithombo:

"Unyango lwe-syeloproliferative neoplasms: nini, yiphi i-agent, kwaye njani?" nguHL Geyer kunye ne-RA Mesa epapashwe ngeGazi ngo-12/4/2014.

Prchal JT, Prchal JF. Isahluko 86. Polycythemia Vera. Ku: Lichtman MA, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT. eds. Williams Hematology, 8e . New York, NY: McGraw-Hill; 2010.